Biovie Inc Stock Price, News & Analysis

BioVie Inc. has appointed Dr. Joseph M. Palumbo as its new Chief Medical Officer. Dr. Palumbo, a veteran in the pharma industry, will oversee the development of therapies for neurodegenerative and liver diseases. He will lead clinical programs such as NE3107, targeting Alzheimer's and Parkinson's diseases, and BIV201, aimed at treating complications of liver cirrhosis. His extensive experience in drug development is expected to enhance BioVie’s clinical operations, improving the potential for successful trials.

BioVie (NASDAQ: BIVI) has received FDA authorization to commence a Phase 2 study evaluating NE3107 for its potential pro-motoric effects in Parkinson's disease patients. This double-blind, placebo-controlled trial will involve 40 participants and assess safety, tolerability, and efficacy through established motor ratings. NE3107 demonstrates promise in reducing neuroinflammation and enhancing insulin sensitivity, critical to neurodegenerative diseases. The company anticipates patient enrollment to begin by late 2021 and topline results by mid-2022.

BioVie Inc. (NASDAQ: BIVI) has announced a webinar on October 26, 2021, addressing neuroinflammation and insulin resistance related to Alzheimer's Disease. Key opinion leaders will discuss the inflammatory mechanisms in Alzheimer's, while BioVie management will outline the clinical progress of NE3107, their treatment candidate targeting Alzheimer's. The NM101 Phase III clinical study for NE3107 has begun, with 316 subjects enrolled for this randomized trial aimed at treating mild to moderate Alzheimer's. This initiative marks a significant step in BioVie’s plans for addressing neurodegenerative disorders.

BioVie Inc. (NASDAQ: BIVI) announced its management team's participation at the Cantor Virtual Global Healthcare Conference from September 27-30, 2021. A presentation is scheduled for September 29, 2021, at 11:20 a.m. EST, with a webcast available for investors. BioVie, focused on innovative therapies for neurological and liver diseases, is also progressing its Phase 2 study for its Orphan drug candidate BIV201 and initiating a Phase 3 study for NE3107 in Alzheimer's disease. More details can be found on their website.

BioVie Inc. (NASDAQ: BIVI) announced its management team's participation in the Oppenheimer Fall Healthcare Life Sciences & MedTech Virtual Summit on September 22, 2021, at 12:25 p.m. EST. This conference will provide an update on BioVie’s innovative drug therapies targeting neurodegenerative disorders and advanced liver disease. BioVie is currently evaluating BIV201 for refractory ascites and plans to initiate a Phase 3 study for hepatorenal syndrome. Additionally, the company is conducting a pivotal study for NE3107, aimed at treating Alzheimer's disease, with results expected in late 2022.

BioVie Inc. (NASDAQ: BIVI) has successfully closed its underwritten public offering, raising $20 million through the sale of 2.5 million shares of Class A common stock at $8.00 each. The offering includes an option for underwriters to purchase an additional 375,000 shares for overallotments. Proceeds will primarily support general corporate purposes. BioVie is advancing drug therapies for neurological disorders, liver diseases, and certain cancers, with notable candidates like BIV201 for liver disease and NE3107 targeting Alzheimer's.

BioVie Inc. (NASDAQ: BIVI) has priced its public offering of 2,500,000 shares of Class A common stock at $8.00 per share, generating gross proceeds of $20,000,000. The underwriters have a 45-day option to purchase an additional 375,000 shares. Proceeds will primarily be used for general corporate purposes. The offering is conducted under a shelf registration statement filed with the SEC. BioVie is developing therapies for neurological disorders and liver disease, including BIV201, which is in clinical trials aimed at addressing significant medical needs.

BioVie Inc. (NASDAQ: BIVI) announced plans for an underwritten public offering of its common stock, with all shares to be sold by the company. The offering is managed by ThinkEquity and is subject to market conditions, with no guarantee on its completion or terms. Proceeds are intended for general corporate purposes. The securities will be offered under a registration statement filed with the SEC. The company is engaged in developing therapies for chronic conditions, including a Phase 2 study of BIV201 for liver disease and a Phase 3 study of NE3107 for Alzheimer's.

BioVie Inc. (NASDAQ: BIVI) has initiated the NM101 Phase III clinical study, enrolling its first patient to test NE3107 for Alzheimer’s Disease. This pivotal study involves 316 subjects and aims to assess cognitive, functional, and behavioral endpoints, as well as brain glucose utilization. NE3107 has shown promise in previous studies for reducing neuroinflammation and insulin resistance, which are associated with cognitive decline in Alzheimer’s. The study's results are expected by the end of 2022.

BioVie is also advancing its liver disease treatment, BIV201, and plans to evaluate NE3107 in Parkinson’s Disease.